• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Differential Impact of Clinical Factors for Predicting High Platelet Reactivity on Clinical Outcomes in Acute Myocardial Infarction Patients Treated With Clopidogrel and Prasugrel
CONCLUSIONS: Clinical factors listed in the HHD-GENE score may help stratify ischemic risks in patients with acute MI treated with clopidogrel and prasugrel, whereas risk stratification without genetic testing in patients treated with clopidogrel may be challenging.PMID:37316266 | DOI:10.5551/jat.64217
Source: Journal of Atherosclerosis and Thrombosis - June 14, 2023 Category: Cardiology Authors: Hiroki Goto Yuichi Saito Tadahiro Matsumoto Takanori Sato Daichi Yamashita Sakuramaru Suzuki Shinichi Wakabayashi Hideki Kitahara Koichi Sano Yoshio Kobayashi Source Type: research

Efficacy and Safety of Ticagrelor and Clopidogrel in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
CONCLUSIONS: Ticagrelor was associated with a lower incidence of MACCEs without an increased risk of bleeding events in patients with SCAD receiving PCI. PMID: 32908113 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - September 12, 2020 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

Association between High Platelet Reactivity Following Dual Antiplatelet Therapy and Ischemic Events in Japanese Patients with Coronary Artery Disease Undergoing Stent Implantation.
CONCLUSION: HTPR was significantly associated with adverse ischemic outcomes at 1 year after PCI in Japanese patients receiving maintenance DAPT, indicating its potential as a prognostic indicator of clinical outcomes in this high-risk patient population. PMID: 31092743 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - May 18, 2019 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.
CONCLUSION: In PCI-treated ACS patients, clopidogrel therapy and PRI VASP ＜61% were not associated with increased risks of thrombotic events compared to prasugrel or ticagrelor therapy. PMID: 29415954 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - February 10, 2018 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research